Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol

Conard, J.; Basdevant, Arnaud; Thomas, Jean-Louis; Ochsenbein, E.; Denis, C.; Guyene, Than Tam; Degrelle, H

doi:10.1016/s0015-0282(16)57909-6

Cited by 64 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six months of treatment with estradiol (2 mg/d) combined with cyclical micronized progesterone (200 mg/d from days 14 to 25) resulted in a 14% increase in F1ϩ2 levels. 20 However, 3 months of treatment with estradiol (1 or 1.5 mg) combined with cyclical nomegestrol acetate (2.5 mg, days 1 to 24) 27 did not increase F1ϩ2, whereas Walsh et al 16 found a 16% increase in F1ϩ2 after 3 to 6 months of treatment with CEE (0.625 mg) and continuous medroxyprogesterone acetate (2.5 mg/d), but this change was not statistically significant.…”

Section: Discussionmentioning

confidence: 96%

Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis

Teede

McGrath

Smolich

et al. 2000

ATVB

124

View full text Add to dashboard Cite

Abstract-Hormone replacement therapy (HRT) appears to be cardioprotective in postmenopausal women; however, concerns exist over its thrombogenic effects. To address the effects of combined HRT on coagulation and fibrinolysis, we have measured circulating markers of these processes in a double-blind placebo-controlled trial. Forty-two healthy postmenopausal women aged 50 to 75 years received continuous combined HRT with 2 mg estradiolϩ1 mg norethisterone or placebo for 6 weeks. Hormone profiles were measured at baseline, and lipid and hemostatic parameters were measured at baseline and after 6 weeks of therapy. Baseline characteristics were similar in the 2 groups. With change from baseline the main outcome measure, HRT increased the markers of coagulation (prothrombin fragments 1ϩ2, 0.

show abstract

Section: Discussionmentioning

confidence: 96%

Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis

Teede

McGrath

Smolich

et al. 2000

ATVB

124

View full text Add to dashboard Cite

show abstract

“…With regard to the norpregnane derivatives, one randomized trial failed to show any changes in hemostatic variables among women receiving oral estrogen combined with nomegestrol acetate. 33 Among women recruited from the Project Aging Women, van Baal et al 34 and Post et al 35 have studied the effect of trimegestone (a norpregnane derivative), dydrogesterone, or both combined with oral estrogen therapy on hemostatic variables. Deleterious effects of oral estrogen therapy on coagulation without significant differences between all progestogen subgroups were found.…”

Section: Discussionmentioning

confidence: 99%

Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women

et al. 2007

Self Cite

View full text Add to dashboard Cite

After adjustment for potential confounding factors, odds ratios (ORs) for VTE in current users of oral and transdermal estrogen compared with nonusers were 4.2 (95% CI, 1.5 to 11.6) and 0.9 (95% CI, 0.4 to 2.1), respectively. There was no significant association of VTE with micronized progesterone and pregnane derivatives (OR, 0.7; 95% CI, 0.3 to 1.9 and OR, 0.9; 95% CI, 0.4 to 2.3, respectively). In contrast, norpregnane derivatives were associated with a 4-fold-increased VTE risk (OR, 3.9; 95% CI, 1.5 to 10.0). Conclusions-Oral but not transdermal estrogen is associated with an increased VTE risk. In addition, our data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect to thrombotic risk. If confirmed, these findings could benefit women in the management of their menopausal symptoms with respect to the VTE risk associated with oral estrogen and use of progestogens. (Circulation.

show abstract

“…pregnancy (7,(10)(11)(12)(13)(14), under the influence of drugs (19,25), oral contraceptives (17) and hormones (19,26,27), including gonadotropins (15,16). Results from animal studies (28) cannot be compared directly with results from humans (5) without due consideration of animal physiology.…”

Section: Resultsmentioning

confidence: 99%

“…pituitary hormones (15,16) and diftrations, together with the wide range of concentrations ferent dru S s (»· I7~19 ) are weU documented, found in serum, allow only non-parametric statistics to be used. In addition, the median value for lipoprotein(a) Subjects and Methods lies in a concentration range where relative few results ooor .…”

Section: Introductionmentioning

confidence: 99%

Do Gonadotropins Influence Serum Lipoprotein(a) Concentrations? Observations on Children, Adolescents and Adults

Schumacher¹,

Weigert²,

Wood³

1996

CCLM

View full text Add to dashboard Cite

Summary:Data from 7045 subjects were examined. The main groups consisted of the following in-and outpatients: 1414 neonates, 2554 children and adolescents (1336 males, 1218 females), 1209 women directly postpartum, 786 non-pregnant women and 1090 men aged between 18 and 100 years of age. Unless otherwise stated, persons were under medical observation or therapy.The results were obtained over a three-year period using an in-house immunolurninometric assay specific for apolipoprotein(a) using two polyclonal antibodies and a single lot of reagents to allow for comparability of results.Girls aged between 10 and 12 years of age had significantly higher serum lipoprotein(a) (median 124 mg/1) levels than boys (median 88 mg/1) of the same age (p < 0.05 -Mann-Wliitney U-test). Post-pubertal lipoprotein(a) concentrations were not significantly different from pre-pubertal levels. Between the ages of 0-9 and 13-17 years there were no statistically significant sex-linked differences in serum lipoprotein(a).In adults, lipoprotein(a) serum levels were significantly higher in women (median 163 mg/1) aged between 50 and 59 years, when compared with men (median 128 mg/1) of the same age group (p = 0.05 -Kruskal-Wallis one way ANOVA followed by the Nemenyi test).There was no significant difference in serum lipoprotein(a) concentrations between healthy women (median 91 mg/1), women direct postpartum (median 116 mg/1) and in-patient women (median 117 mg/1) aged between 18 and 41 years of age (p = 0.11-0.96). There was no correlation between maternal lipoprotein(a) and birth weight in mature newborns (r = -0.028-0.085).The results may indicate a direct influence of gonadotropins at puberty and during the menopause which cause an increase in serum lipoprotein(a) concentrations.

show abstract

Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol

Cited by 64 publications

References 15 publications

Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis

Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis

Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women

Do Gonadotropins Influence Serum Lipoprotein(a) Concentrations? Observations on Children, Adolescents and Adults

Contact Info

Product

Resources

About